Sphera Funds Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Sphera Funds Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-778,800	Closed	-$935K	–	153
2017 Q1	$935K	Sell	778,800 -200,000	-20%	-$250K	0.18%	95
2016 Q4	$1.29M	Buy	978,800 +114,993	+13%	+$200K	0.33%	76
2016 Q3	$1.8M	Buy	+863,807	New	+$1.71M	0.29%	78
2015 Q1	–	Sell	-100,000	Closed	-$997K	–	190
2014 Q4	$997K	Buy	+100,000	New	+$853K	0.17%	110
2014 Q1	–	Sell	-120,000	Closed	-$2.2M	–	152
2013 Q4	$2.2M	Buy	+120,000	New	+$2.27M	0.61%	42

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sphera Funds Management's RPRX Position: Q2 2017 in Review

Sphera Funds Management sold out of Repros Therapeutics Inc. (RPRX) in Q2 2017, closing a stake of 778,800 shares — an estimated $935K sold.

Sphera Funds Management first reported a position in RPRX in Q4 2013 and held it in 5 quarters. The position peaked at $2.2M in Q4 2013. 29 funds tracked by Wall St. Rank hold RPRX as of Q2 2017.

Sphera Funds Management reported no remaining Repros Therapeutics Inc. position as of Q2 2017 after selling out during the quarter.
Sphera Funds Management sold 778,800 Repros Therapeutics Inc. shares in Q2 2017, an estimated $935K.
Sphera Funds Management first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 5 quarters.
Sphera Funds Management's Repros Therapeutics Inc. position peaked at $2.2M in Q4 2013.
29 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2017.

Based on Sphera Funds Management's 13F filing for Q2 2017, filed 9 Aug 2017.